TIRmed Pharma collaborates with Bachem
The collaboration includes process development and manufacturing of TIR-01, the active substance in TIRmed’s treatment for atopic dermatitis (eczema), and marks an important step towards future clinical trials.
November 18, 2025
As part of its preclinical program, TIRmed Pharma is collaborating with Bachem to establish high-quality production processes for TIR-01, an oligonucleotide-based compound, they describe in a press release.
Oligonucleotide production
With its expertise in oligonucleotide production, Bachem provides critical expertise for GMP development, ensuring stability, consistency and regulatory compliance for upcoming clinical studies according to the company.
“The collaboration with Bachem is an important milestone in the work of taking our drug candidate further towards the clinic,” says Leo Holmgren, CEO of TIRmed Pharma.
“It gives us access to world-leading manufacturing expertise and strengthens the foundation for being able to offer patients a longer-term treatment alternative,” he adds.
Learn more about the science behind TIRmed Pharma and its connections to this year’s Nobel Prize in Medicine in our latest issue of the magazine – out now!
Published: November 18, 2025
